PTC Therapeutics posts Q3 net loss
PTCT•PTC Therapeutics reported a third-quarter net loss of $51.69 million, compared with a profit a year earlier, and raised its 2026 total revenue outlook to $1.29 billion-$1.32 billion.
1. Raised revenue outlook
PTC Therapeutics raised its 2026 total revenue outlook to $1.29 billion-$1.32 billion and product revenue guidance to $960 million-$990 million, from $850 million-$950 million. It maintained 2026 GAAP research and development and selling, general and administrative expense guidance at $775 million-$815 million.
2. Quarterly results
The company posted a third-quarter net loss of $51.69 million, or $0.62 per basic share. Operating expenses were $332.69 million, and operating income was $25.11 million.
3. Sephience sales
PTC said Q3 revenue growth was driven by continued momentum and expansion of Sephience. Sephience sales rose 20% sequentially in the quarter.
